Currently out of the existing stock ratings of Daniil Gataulin, 102 are a BUY (86.44%), 16 are a HOLD (13.56%).

Daniil Gataulin

Work Performance Price Targets & Ratings Chart

Analyst Daniil Gataulin, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 29.58% that have a potential upside of 44.5% achieved within 179 days.

Daniil Gataulin’s has documented 209 price targets and ratings displayed on 19 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on KOD, Kodiak Sciences at 11-May-2026.

Wall Street Analyst Daniil Gataulin

Analyst best performing recommendations are on CRVO (CERVOMED).
The best stock recommendation documented was for CRVO (CERVOMED) at 3/13/2025. The price target of $14 was fulfilled within 8 days with a profit of $8.21 (141.8%) receiving and performance score of 177.25.

Average potential price target upside

of $19.9 (153.84%) on QURE (UNIQURE NV).
of $13.2 (96.77%) on OCS (OCULIS HOLDING AG ORDINARY SHARES).
of $12.66 (158.96%) on EYPT (EYEPOINT PHARMACEUTICALS).

ADVM Adverum Biotechnologies AGTC Applied Genetic KOD Kodiak Sciences OCGN Ocugen OYST Oyster Point Pharma RGNX Regenxbio EYPT Eyepoint Pharmaceuticals FREQ Frequency Therapeutics OTLK OUTLOOK THERAPEUTICS INC FBRX Forte Biosciences CGTX Cognition Therapeutics CRVO CervoMed OCS Oculis Holding AG Ordinary shares CLSD Clearside Biomedical MGTX MeiraGTx Holdings PLC OCUL Ocular Therapeutix QURE Uniqure NV TRML Tourmaline Bio ANNX Annexon

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Matthew Caufield (HC WAINWRIGHT)